Pliant Therapeutics: Exploring Innovations in Lung Disease Treatment
Pliant Therapeutics to Present at the American Thoracic Society Conference
Pliant Therapeutics, Inc. (Nasdaq: PLRX), an innovative biopharmaceutical company based in South San Francisco, has recently announced its participation in the 2025 American Thoracic Society (ATS) International Conference set to occur from May 16-21. This prominent event focuses on the latest advances in respiratory health and will see Pliant showcasing its significant research findings.
Highlighted Presentations at ATS 2025
Pliant is excited to present three science-based posters during this prestigious conference, highlighting key advancements in understanding and treating fibrotic diseases. One of the standout features for Pliant is its inclusion in the ATS 2025 Mini Symposiums program, where it will give a featured oral presentation.
Understanding Bexotegrast's Antifibrotic Effects
One of the highlighted oral presentations at the conference will be led by Johanna Schaub, Ph.D., the Director of Translational Sciences at Pliant Therapeutics. The presentation, titled "Characterizing the Antifibrotic Activity of Bexotegrast on Distinct Fibroblast Populations in PCLS From Multiple ILD Subtypes," is set for May 19. This research will delve into how bexotegrast interacts with different fibroblast populations, which is crucial for understanding its potential in treating idiopathic pulmonary fibrosis (IPF).
Identifying Biomarkers for ILD Subtypes
Another significant poster presentation will explore the findings of Richard Ahn, Ph.D., Pliant's Senior Scientist II. The poster, titled "Plasma Proteome Analysis Reveals Shared and Unique Biomarkers of ILD Subtypes," will be showcased on May 21. This research is essential for developing targeted therapies for various interstitial lung diseases (ILD) by revealing unique biomarkers associated with different disease subtypes.
Pliant's Commitment to Advancing Fibrotic Disease Treatments
In addition to these presentations, another important piece of research will be presented by Mahru An, Ph.D., Principal Scientist at Pliant Therapeutics. Her presentation on the "Single-Cell Profiling Demonstrates the Antifibrotic Effects of Bexotegrast on Pathologic Lung Cell Populations" will also take place on May 21. Understanding how bexotegrast can modulate lung cell populations is a vital step toward optimizing its therapeutic applications.
The presentations will be available for registered attendees from May 18 through May 21, offering a unique opportunity to engage with Pliant's research team and learn more about the groundbreaking work they are doing in fibrosis and lung diseases.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is at the forefront of developing innovative treatments for fibrotic diseases. The company's leading candidate, bexotegrast, is a novel oral therapy designed to selectively inhibit integrins that play a significant role in the progression of pulmonary fibrosis. Bexotegrast has been granted Fast Track and Orphan Drug Designations by the FDA and is recognized for its potential to transform the treatment landscape for IPF.
Beyond bexotegrast, Pliant is also advancing PLN-101095, another dual selective inhibitor, and has regulatory clearance for its Phase 1 study targeting muscular dystrophies with PLN-101325, an integrin agonist. These developments underscore Pliant's commitment to offering hope for patients affected by serious fibrotic conditions.
Frequently Asked Questions
What is the significance of the ATS 2025 conference for Pliant?
The ATS conference allows Pliant to showcase their groundbreaking research in the field of fibrotic diseases, promoting awareness and collaboration with leading experts.
Who will present on behalf of Pliant at the conference?
Presenters include Dr. Johanna Schaub, Dr. Richard Ahn, and Dr. Mahru An, who will discuss their research on bexotegrast and its effects on fibrotic diseases.
What is bexotegrast?
Bexotegrast is Pliant's leading therapy targeting pulmonary fibrosis, functioning as a dual selective inhibitor of specific integrins involved in fibrosis progression.
What are the goals of Pliant's research?
Pliant aims to develop effective treatments for fibrotic diseases, significantly improving patient outcomes and addressing unmet medical needs.
Where can additional information about Pliant be found?
More details about Pliant Therapeutics and their research can be found on their official website, providing comprehensive insights into their initiatives and therapeutic developments.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
